Download the free e-book on peptides, hormones and pharmaceuticals for longevity, health and performance here: get the e-book
AOD-9604: What the Evidence Actually Shows and Why the Debate Is Worth Having
There are compounds in the optimization space where the evidence is clear, the mechanism is well established, and the clinical outcomes are consistent enough that the conversation is relatively straightforward. AOD-9604 is not one of those compounds.
AOD-9604 has a genuinely interesting mechanism, a favorable safety profile, a Phase 2 signal that attracted serious pharmaceutical investment, and a Phase 3 failure that ended its commercial development. It also has a substantial following in the optimization and body composition community that continues to use it despite the mixed clinical record.
This article presents both sides of that picture honestly, because the honest picture is more useful than either uncritical promotion or dismissal.
What AOD-9604 is
AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176 through 191 of the human growth hormone sequence, with a tyrosine residue added to the N-terminus for stability. The name stands for Anti-Obesity Drug 9604 and reflects its origin as a pharmaceutical development project by Metabolic Pharmaceuticals in Australia, which conducted the clinical program through the late 1990s and 2000s with the intention of developing it as a pharmaceutical treatment for obesity.
The concept behind it is elegant. Growth hormone produces multiple effects through different receptor interactions and different downstream signaling pathways. The lipolytic effects, the fat-burning dimension of growth hormone, are mediated through a specific region of the molecule. AOD-9604 isolates that region, theoretically capturing the fat metabolism effects while leaving behind the anabolic, IGF-1 stimulating, and glucose-affecting properties of full growth hormone.
The case for AOD-9604
The mechanistic argument is sound. The lipolytic region of growth hormone is well characterized in the research literature, and AOD-9604 does interact with it in ways consistent with its proposed mechanism. It stimulates lipolysis through beta-3 adrenergic receptor activation and direct effects on adipose tissue metabolism, promoting the mobilization of stored fat without the systemic growth hormone effects that create complications at higher doses.
The safety profile across the clinical trials is genuinely favorable. Unlike full growth hormone, AOD-9604 does not stimulate IGF-1 production, does not significantly affect blood glucose or insulin sensitivity, and does not suppress natural growth hormone production through pituitary feedback. For people concerned about the systemic effects of growth hormone-related compounds, AOD-9604's targeted mechanism is a real advantage.
Phase 2 trials produced a statistically significant signal on fat loss, specifically abdominal fat reduction, that was sufficient to advance the compound to Phase 3 investigation. That signal was not trivial — it represented a real effect on a meaningful endpoint in a controlled population. The preferential reduction of abdominal fat observed in Phase 2 is consistent with the regional distribution of beta-3 adrenergic receptors in adipose tissue and supports the mechanism rather than contradicting it.
In the optimization context, where people are actively managing nutrition and activity rather than simply receiving a compound in an uncontrolled lifestyle setting, the argument is that the fat loss signal observed in Phase 2 can express itself more clearly than in a general population trial. This is the population where AOD-9604's mechanism has the most favorable conditions to produce meaningful results.
The case against
The Phase 3 trial failure is not a footnote. It is the most rigorous test AOD-9604 was put through and it did not pass its primary endpoint. In the largest, most controlled human trial conducted on this compound, the result was negative.
The post-hoc rationalization for why Phase 3 failed, that the endpoint was total body weight rather than fat mass specifically, and that the population was uncontrolled, is the kind of argument that gets applied to many failed pharmaceutical compounds. It is reasonable but it is also convenient, and the scientific community is rightly skeptical of arguments that reframe a failed trial as a success that was simply measured incorrectly.
The commercial development program was discontinued and has never been restarted. If the Phase 2 signal and the mechanistic rationale were sufficiently compelling, the expectation would be that someone would have redesigned the Phase 3 trial with a fat mass primary endpoint and an active lifestyle inclusion criterion. That has not happened in the roughly two decades since the program ended.
The evidence base that circulates in the optimization community is predominantly anecdotal, extrapolated from Phase 2 data, or based on mechanistic arguments that assume the compound works as designed without clinical verification at the population level that Phase 3 failed to provide.
Compared to other fat loss compounds in the catalogue, AOD-9604 sits at a significantly lower level of clinical evidence. The GLP-1 compounds have multiple large randomized controlled trials, regulatory approvals, and post-market safety data spanning years. MOTS-C has a well-characterized mechanism with consistent preclinical data. AOD-9604 has a positive Phase 2 and a negative Phase 3.
The honest synthesis
AOD-9604 is a compound where intellectual honesty requires holding two things simultaneously.
The mechanism is real and the safety profile is favorable. For people in an active optimization program who are managing nutrition carefully, there is a reasonable mechanistic argument for including it as a targeted fat mobilization adjunct. The Phase 2 signal, while not enough for pharmaceutical approval, was not nothing. And the absence of IGF-1 stimulation and glucose effects is a genuine advantage over alternatives that affect those systems.
At the same time, the Phase 3 failure means the compound has not cleared the evidentiary bar that would justify confident clinical claims about its fat loss efficacy. The optimization community's enthusiasm for AOD-9604 runs ahead of what the clinical evidence supports, and people considering it should understand that they are operating on mechanistic rationale and Phase 2 signal rather than Phase 3 confirmation.
That is not necessarily a reason to avoid it, particularly given the favorable safety profile. It is a reason to calibrate expectations appropriately, to understand the difference between a compound with strong evidence and a compound with interesting evidence, and to prioritize higher-evidence options when the clinical picture is the primary consideration.
For people who have tried the higher-evidence fat loss options and are looking for additional targeted support, or for whom the specific advantage of no IGF-1 or glucose effects is clinically meaningful, AOD-9604 is a reasonable option with realistic expectations attached. For people making their first decisions about fat loss intervention, the GLP-1 class offers substantially stronger evidence and substantially more predictable outcomes.
That is the honest picture. The debate about AOD-9604 is worth having precisely because the evidence does not resolve it cleanly in either direction.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before making any changes to your health regimen. For more information visit www.peakformrx.health